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CHAPTER 1 
 
INTRODUCTION 
 
Anatomy and Physiology of the Head and Neck  
Epithelial Tissue Structure and Function 
 Epithelial cells cover the outside of the body and line the organs and cavities, including 
the oral cavity, throat, and nasal cavity [1]. They are located close to each other, and the 
membranes of adjacent epithelial cells join together to create tight junctions [1]. Epithelial cells 
serve to protect the body from foreign intruders and mechanical damage from outside the body 
as well as to form glands, which serve the function to secrete or absorb. Cell shape and the 
number of cell layers are criteria used for describing epithelial cells. Simple epithelium describes 
a single layer of cells, whereas stratified epithelium describes multiple layers of cells. Epithelial 
cells can be cuboidal (cube-shaped), columnar (shaped like a rectangular prism), or squamous 
(flat and long) [2]. Figure 1 illustrates the difference between these cell types. Squamous cells 
create linings for organs and allow for diffusion across these barriers [3]. Additionally, epithelial 
cells exhibit polarity, in which an apical membrane faces the lumen, whereas the basolateral 
membrane faces the basement membrane [4]. 
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Figure 1: Epithelial cell characterization. Epithelial cells are characterized by their shape and 
number of layers [2]. 
 
More than 85% of cancers originate in the epithelium [5]. One side of the epithelia is 
exposed to the exterior environment, and the other side of the epithelia is adjacent to the 
basement membrane (Figure 2). Metastasis can occur after cancer cells break through basement 
membrane. The epithelial layer is avascular. 
 
Figure 2: Anatomy of epithelial cells. Epithelial cells are exposed on one side and adjacent to 
the basement membrane on the other side [6]. 
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Head and Neck Anatomy and Physiology 
The head and neck region includes the nasal cavity, oral cavity, pharynx, and larynx. 
These organs work together to perform critical functions, including chewing and swallowing 
food, speaking, and breathing.  
 
 
Figure 3: Anatomy of the head and neck region. Head and neck squamous cell carcinoma 
originates in squamous cells of the oral cavity, nasal cavity, pharynx, and larynx [7]. 
 
The oral cavity includes the lips, teeth, jaw, tongue, roof of the mouth, floor of the mouth, 
and salivary glands. The lips form the opening of the mouth and they are important in speech and 
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containing food in the mouth. The tongue helps guide food and contains taste buds. The main 
function of the oral cavity is to chew and break down food mechanically using teeth and 
chemically using saliva produced by salivary glands.  
The pharynx is a five-inch long tube located between the nose and the esophagus, and it 
consists of the nasopharynx, oropharynx, and hypopharynx. This cavity in the throat connects the 
nasal and oral cavities with the rest of the respiratory and digestive system, including the 
stomach, small intestine, and large intestine. Swallowing occurs in the pharynx, moving food 
from the mouth into the esophagus.  
The larynx is situated below the pharynx. It is also called the voice box because it 
contains vocal chords that create sound and control pitch and volume. During swallowing, the 
larynx is elevated and the vocal chords move towards each other to move food through the 
esophagus and prevent it from going into the trachea, which leads to the lungs. The epiglottis, a 
layer of cartilage, moves over the laryngeal opening to prevent food from going into the 
respiratory pathways. The esophagus connects the pharynx to the stomach, where food is stored 
and broken down.  
 
Head and Neck Squamous Cell Carcinoma 
Risk Factors and Diagnosis 
 Head and neck squamous cell carcinoma (HNSCC) originates in squamous cells of the 
oral cavity, nasal cavity, pharynx, and larynx. The hallmarks of cancer include evading 
apoptosis, self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue invasion 
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and metastasis, and limitless replicative potential [6]. More than 90% of head and neck cancers 
are squamous cell carcinoma [8].  
Incidence and mortality of HNSCC is correlated with long-term use of tobacco and 
alcohol. About 75% of HNSCC incidence occurs in men compared with 25% in women [9]. The 
stereotypical HNSCC patient is above 50 years old, but the younger population of HNSCC 
patients is increasing. In particular, this increase has been attributed to the prevalence of human 
papilloma virus (HPV), which affects about 25% of HNSCC cases [10][11]. Additionally, poor 
diet, particularly lacking vitamin A and iron, and poor oral hygiene can increase risk for 
developing HNSCC [12]. 
Early symptoms of HNSCC are usually vague. Symptoms of cancer in the oral cavity 
include persistent abnormal masses and sores [13]. Symptoms of cancer in the oropharynx, 
hypopharynx, and larynx include difficulty swallowing, sore throat, and hoarseness or other 
changes in voice quality. Symptoms of cancer in the nasal cavity include difficulty breathing 
through the nose and inflammation of the sinuses [14]. Screening is conducted using physical 
examination to inspect ulcers within the mouth and throat, palpation of the neck, and endoscopy. 
Additionally, magnetic resonance imaging (MRI), x-ray, and computed tomography (CT) can be 
used to detect HNSCC [15]. HNSCC is diagnosed by pathologic examination of surgical biopsy. 
Unfortunately, most cases are diagnosed at advanced stages, so effective treatment options are 
crucial to prevent unnecessary mortality and morbidity. 
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Treatment Techniques and Monitoring of Response 
 Treatment techniques for HNSCC depend on the stage, location, and resectability of the 
primary tumor. Early stages are usually treated with surgery to remove tumor-containing tissue 
and radiation, while advanced stages are treated with surgery and radiation in combination with 
chemotherapy, including cisplatin and fluorouracil (FU). Targeted therapies have also been 
investigated. HNSCC exhibits upregulation of epidermal growth factor receptor (EGFR) in more 
than 90% of cases [16]. EGFR activation leads to growth and proliferation of epithelial cells 
(Figure 4). Cetuximab is a monoclonal antibody that binds to EGFR, prevents activation, and 
leads to receptor degradation, and it has been used to inhibit EGFR-expressing tumors. 
Cetuximab is approved in combination with radiation therapy in patients with locally advanced 
HNSCC. However, since only a portion of patients respond to EGFR inhibitors, downstream 
targets have the potential to improve patient outcomes. Commonly mutated targets include 
phosphoinsitide 3-kinase (PI3K), signal transducer and activator of transcription 3 (STAT3), 
mammalian target of rapamycin (mTOR), Akt, vascular endothelial growth factor receptor 
(VEGFR), NF-κB, and human epidermal growth factor receptors 2 (HER2) and 3 (HER3) [17] 
[18]. 
 Figure 4
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Optical Techniques for Head and Neck Squamous Cell Carcinoma 
Detection of Head and Neck Squamous Cell Carcinoma 
HNSSC is an ideal target for optical imaging because of easy access to the site using fiber 
optic probes [23][24]. Additionally, fiber optics can be incorporated into endoscopes that are 
currently in use. 
Optical techniques have been investigated to detect HNSCC. High-resolution 
microendoscopic imaging has been used to distinguish cancerous versus benign sites for 
assessing tumor margins in surgery for HNSCC [23]. Additionally, fluorescence spectroscopy 
has been shown to identify oral neoplasias with sensitivities and specificities greater than 88% 
[25]. Reflectance spectroscopy using polarized light has also been shown to non-invasively 
extract morphologic information to detect neoplasia in epithelial tissue phantoms and oral tissue 
in vivo [26]. Muller, et al. combined intrinsic fluorescence spectroscopy, diffuse reflectance 
spectroscopy, and light scattering spectroscopy and achieved a sensitivity and specificity of 96% 
and 96% in distinguishing dysplasia from normal tissue in HNSCC patients [27]. Contrast 
agents, particularly acetic acid, and blue-white light have been used to identify premalignancy in 
the oral cavity, but clinical studies will be required to determine the sensitivity and specificity of 
these techniques [28].  
Attempts have been made to monitor treatment response in HNSCC using fluorescently-
labeled antibodies. In one study, mice with HNSCC xenografts treated with fluorescently-labeled 
cetuximab decreased in tumor size, but tumor fluorescence did not correlate with response to 
treatment [29]. Gleysteen et al. used a similar approach of growing xenografts and treating the 
mice with fluorescently labeled cetuximab, cisplatin, and radiation. They found no change 
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among fluorescence intensity before treatment, after six weeks of treatment, or at ten weeks of 
treatment, although tumor regression was observed based on histological analysis. This indicates 
that fluorescence intensity of labeled cetuximab does not reflect tumor response [30]. However, 
endogenous fluorescence has not been studied to measure treatment response in HNSCC.  
  
Two-Photon Fluorescence Microscopy and Fluorescence Lifetime Imaging 
 Light can be described as packets of energy in photons. Fluorescence occurs when a 
molecule absorbs a photon of a particular energy and emits a photon of a different energy [31]. 
This absorption excites the molecule from the ground state, S, to the excited state, S*, and upon 
relaxation the emitted light has an energy less than the absorbed energy (Figure 5). Energy and 
wavelength are inversely related according to E = hc/λ, where E represents energy, h represents 
Planck’s constant, λ represents wavelength, and c represents the speed of light. Therefore, a 
lower energy corresponds to a longer wavelength. Endogenous fluorophores, including NADH, 
FAD, tryptophan, collagen, and elastin, occur naturally in the body, and probing these can 
eliminate the need for dyes or contrast agents [32].  
Two-photon excitation occurs by simultaneous absorption of two photons with half the 
energy required for single-photon excitation (Figure 5) [33]. Photons with half the energy 
correspond to twice the wavelength. Most endogenous fluorophores are excited in the ultraviolet 
(UV) to visible range (~300-500nm), so therefore two-photon excitation uses near-infrared (NIR) 
light (~700-900nm) for excitation [32]. UV or visible light is constrained to a penetration depth 
of about 100µm below tissue surface, whereas decreased scattering and absorption for NIR light 
allows for deeper penetration [34]. Additionally, since the absorption of two photons is required 
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for excitation, sufficient photon flux is only present at the focal point, whereas single-photon 
excitation can produce fluorescence outside the focal point due to scattering (Figure 6). This 
allows for precise depth-sectioning and elimination of out-of-focus signal.  
 
Figure 5. Absorption and fluorescence emission energy diagram. Single-photon (blue) and 
two-photon (red) excitation causes fluorescence emission (green) [35].  
 
 
Figure 6. Comparison between single-photon and two-photon excitation. Single-photon 
fluorescence causes excitation at the focal point and outside the focal point (top), whereas two-
photon fluorescence causes excitation only at the focal point (bottom) [36].  
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Fluorescence lifetime imaging probes the amount of time that a fluorophore is in the 
excited state before relaxing to the ground state [31][37]. The lifetime is sensitive to the 
microenvironment, including protein-binding, pH, and oxygen. In particular, the lifetime 
discriminates between free and protein-bound conformations of molecules. To calculate the 
lifetime, a histogram of the lifetime events is plotted and fit to an exponential curve. The number 
of components in the exponential curve depends on the number of molecular species or binding 
configurations present. For example, NADH and FAD exist in free and protein-bound 
conformations, so these lifetime histograms are fit to a two-component exponential function: F(t) 
= α1e-t/τ1+ α2e-t/τ2, where F represents the fluorescence as a function of time, α represents the 
contribution from each component and τ represents the lifetime of each component (figure 7). 
The lifetime occurs on the order of picoseconds to nanoseconds. Applying two-photon 
fluorescence and fluorescence lifetime imaging of the metabolic cofactors NADH and FAD can 
provide insight into cellular metabolism and microenvironment in vitro and in vivo [38]. 
 
Figure 7. Fluorescence lifetime decay curve. The fluorescence lifetime is calculated by fitting 
the lifetime events (blue) to an exponential function (red).
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CHAPTER 2 
 
OPTICAL METABOLIC IMAGING OF TREATMENT RESPONSE IN HUMAN HEAD AND 
NECK SQUAMOUS CELL CARCINOMA 
 
Introduction 
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cancer by 
incidence in the world [21]. Each year, 500,000 new cases are diagnosed with a five-year 
survival rate between 40-50% [21]. Current standards of care for HNSCC patients include 
surgery, radiation therapy, and chemotherapy. However, surgeries often cause serious 
morbidities by impairing the ability to speak, chew, and swallow. Additionally, radiation therapy 
and chemotherapy introduce toxicities causing nausea, diarrhea, rash, dry mouth or thickened 
saliva, and changes in taste [13]. These negative side effects from HNSCC treatment justify the 
need for improved treatments and the development of biomarkers of early treatment efficacy.  
Current measures of treatment response in HNSCC include x-ray computed tomography 
(CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). However, 
these methods are only effective weeks to months after treatment begins and require contrast 
agents and/or expensive equipment. Alternative treatment options for non-responders include re-
irradiation, chemotherapy, or surgery [39]. Early predictors of drug efficacy would reduce 
toxicities, costs, and time associated with ineffective therapy. Therefore, there is a need for a 
cost-effective, noninvasive tool to determine treatment response at an early timepoint.  
Therapeutic interventions for HNSCC include traditional chemotherapy and targeted 
inhibitors.  Cisplatin is a common chemotherapy used in HNSCC [40]. In the past decade, 
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targeted inhibitors have been developed to treat HNSCC. More than 90% of HNSCC cases 
exhibit upregulation of epidermal growth factor receptor (EGFR). The EGFR signaling pathway 
drives cell proliferation, growth, and survival. EGFR is the only proven molecular target for 
HNSCC therapy [39]. Cetuximab is a monoclonal antibody that inhibits EGFR activation, but 
clinical outcomes with cetuximab treatment have been poor and are not correlated with EGFR 
protein expression levels [41]. Therefore, downstream effectors, including phosphatidylinositol 
3-kinase (PI3K) and mammalian target of rapamycin (mTOR), have been investigated as 
potential therapeutic targets. PI3K, a master regulator of metabolism, is mutated in about 37% of 
HNSCC [42]. BGT226 is a PI3K/mTOR inhibitor currently under clinical investigation for solid 
tumors [43]. However, there is a need for improved technologies to guide the selection of drugs 
for individual patients, so that alternative treatments such as BGT226 can be used at an early 
timepoint. 
The EGFR and PI3K/mTOR signaling pathways regulate cellular metabolism, including 
glycolysis and oxidative phosphorylation. Cancer often exhibits altered metabolism, particularly 
increased aerobic glycolysis (Warburg effect) [44]. During glycolysis, NAD+ is reduced to 
nicotinamide adenine dinucleotide (NADH). During oxidative phosphorylation, NADH is 
oxidized to NAD+ and FADH2 is oxidized to flavin adenine dinucleotide (FAD). NADH and 
FAD exhibit autofluorescence, whereas NAD+ and FADH2 do not. The optical redox ratio, 
defined as the fluorescence intensity of NADH divided by the fluorescence intensity of FAD, 
reflects relative amounts of glycolysis compared with oxidative phosphorylation and is an 
established method for probing cellular metabolism [38][45][46]. The fluorescence lifetime is the 
time a fluorophore stays in the excited state before relaxing to the ground state and reflects 
fluorophore microenvironment, including protein-binding and preferred metabolic pathways 
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[31]. The optical redox ratio and fluorescence lifetimes of NADH and FAD exploit intrinsic 
contrast to measure optical endpoints of cellular metabolism. Furthermore, metabolic endpoints 
show particular promise because shifts in cellular metabolism often occur sooner than changes in 
tumor size or glucose uptake. 
Tissue autofluorescence has been previously used to detect HNSCC. The 
autofluorescence intensity of NADH and FAD has been used to distinguish normal from 
dysplasia in oral tissue [47], and the NADH and FAD fluorescence lifetimes have been shown to 
identify precancer compared with normal in the DMBA-treated hamster cheek pouch model 
[48][49][50][51]. Multiphoton microscopy of endogenous fluorescence has been used to quantify 
cellular and tissue morphology in the DMBA-treated hamster cheek pouch model [52][53]. 
However, no previous literature has characterized endogenous fluorescence in response to 
treatment in HNSCC. Fluorescent dyes have been used to monitor anti-EGFR antibody uptake in 
HNSCC, but results did not reflect response in vivo [29][30]. Optical metabolic imaging is 
sensitive to early metabolic shifts after cancer treatment and has potential to noninvasively detect 
treatment response sooner than current methods. 
The serious morbidities and toxicities from HNSCC treatment justify the need for early 
predictors of treatment efficacy. This study tests the hypothesis that autofluorescence from 
metabolic cofactors NADH and FAD can resolve response to targeted therapies and 
chemotherapy in HNSCC. Optical metabolic imaging was performed on two HNSCC cell lines, 
SCC25 and SCC61, treated for 24 hours with targeted drugs (cetuximab or BGT226) or 
chemotherapy (cisplatin). HNSCC is an ideal site for optical imaging because of easy access to 
the site with fiber optic probes. These results indicate that optical metabolic imaging has 
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potential to expedite drug screenings, develop optimal treatments, and improve patient outcomes 
for HNSCC.  
 
Materials and Methods 
 
Cell Culture and Reagents 
The TERT-immortalized human oral keratinocyte line OKF6/TERT-1 (OKF6), the 
squamous cell carcinoma line SCC25, and the squamous cell carcinoma line SCC61 were 
acquired from J. Rheinwald and the Cell Culture Core of the Harvard Skin Disease Research 
Center, Boston, MA [54]. OKF6 cells were cultured in keratinocyte serum-free medium (GIBCO 
K-sfm; Invitrogen) supplemented with 25g/ml bovine pituitary extract, 1% 
penicillin/streptomycin, 0.2ng/ml epidermal growth factor, and 0.3mM CaCl2. SCC25 and 
SCC61 cells were cultured in DMEM/F12 media (Invitrogen) supplemented with 10% fetal 
bovine serum and 0.4µg/ml hydrocortisone (Sigma).  
For fluorescence imaging, 105 cells were plated on 35 mm glass-bottomed dishes 
(MatTek Corp.). The media was replaced 24 hours after plating with control media or treatment 
media containing 13nM (1.90 µg/mL) cetuximab (Vanderbilt Pharmacy), 300nM NVP-BGT226 
(Selleckchem), or 176µM cisplatin (Selleckchem). The drug doses were chosen to be 11 times 
the IC50 for each  drug [55] [56] [57]. The cells were imaged 24 hours after treatment.  
 
Imaging Instrumentation 
Fluorescence lifetime images were collected using a custom-built multi-photon 
fluorescence microscope (Prairie Technologies). Images were acquired through an inverted 
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microscope (TiE, Nikon) with a 40x oil immersion objective (1.3 NA). Fluorescence was excited 
using a titanium:sapphire laser (Chameleon, Coherent Inc.) and collected using a GaAsP 
photomultiplier tube (H7422P-40, Hamamatsu). NADH and FAD images were acquired 
sequentially for the same field of view. NADH fluorescence was isolated using an excitation 
wavelength of 750nm and an emission bandpass filter of 400-480nm. FAD fluorescence was 
isolated using an excitation wavelength of 890nm and an emission bandpass filter of 500-600nm. 
The average power incident on the sample was approximately 10mW. The acquired images 
consisted of 256 x 256 pixels (170m x 170m) with a 4.8s pixel dwell time. Time-correlated 
single photon counting (TCSPC) electronics (SPC-150, Becker and Hickl) were used to collect 
fluorescence lifetime images over 60 seconds. The absence of photobleaching was confirmed by 
monitoring photon count rates throughout image acquisition.  
The instrument response function (IRF) was measured from second harmonic generation 
of urea crystals excited at 900nm, and the full width at half maximum (FWHM) was calculated 
to be 244 ps. A Fluoresbrite YG microsphere (Polysciences Inc.) was imaged as a daily standard. 
The lifetime decay curves were fit to a single exponential decay and the fluorescence lifetime 
was measured to be 2.13 ± 0.28ns (n=7), which is consistent with published values [49][58]. 
 
Cyanide Perturbation 
The OKF6 cells were plated at a density of 105 cells per 35 mm glass-bottomed dish 
(MatTek Corp.). After 48 hours, fluorescence lifetime images of NADH and FAD were acquired. 
Then, the media was replaced with cyanide-supplemented media (4mM NaCN, Sigma). After 
five minutes of cyanide treatment, fluorescence lifetime images of NADH and FAD were 
acquired.  
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Image Analysis 
Fluorescence lifetime images were analyzed using SPCImage software (Becker and 
Hickl). Binning included the selected pixel and the eight surrounding pixels. The fluorescence 
lifetimes were calculated by de-convolving the measured fluorescence decay curve with the IRF 
and fitting to a two-component exponential curve, F(t) = α1e-t/τ1 + α2e-t/τ2 + c. F(t) represents the 
fluorescence intensity as a function of time after the excitation pulse, τ1 and τ2 represent the short 
and long fluorescence lifetimes, respectively, α1 and α2 represent the contribution from each 
lifetime component (α1+α2=1), and c represents background light. A two-component decay curve 
was chosen to represent free and protein-bound conformations of NADH and FAD [49]. The 
weighted mean lifetime, τm, was calculated, τm = α1τ1+α2τ2. The photon counts per pixel were 
summed over the 60 second collection time to calculate a fluorescence intensity image. A 
threshold was applied to exclude fluorescence from background and cell nuclei. The 
fluorescence intensities and lifetime values were imported into MATLAB (Mathworks) for 
further quantification. Redox ratio images were calculated by dividing the fluorescence intensity 
image of NADH by the fluorescence intensity image of FAD for the same field of view, and the 
average per image was computed. The redox ratio was normalized to control cells for comparing 
treatment groups within cell lines. The redox ratio was normalized to the nonmalignant OKF6 
cells when comparing between cell lines. Average fluorescence lifetime values were calculated 
per image. 
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Western Blotting Analysis 
Cells were plated at 3*106 cells per 10cm dish. After 24 hours, the media was removed, 
the cells were washed three times with phosphate buffered saline (PBS), and serum-free media 
was added. After another 24 hours, the media was replaced with treatment media for one hour. 
For the groups treated with epidermal growth factor (EGF) or transforming growth factor alpha 
(TGF-α), 10ng/mL EGF or TGF-α was added for 5 minutes. The cells were lysed with lysis 
buffer (1% Triton X-100, 10% Glycerol, 50 mM HEPES pH 7.2, and 100 mM NaCl) 
supplemented with sodium orthovanadate and protease inhibitor cocktail. Proteins were 
separated using a 10% SDS-PAGE separation gel at 100V. The gel was transferred at 27V 
overnight to a PVDF membrane. The membrane was blocked using 5% bovine serum albumin 
(BSA) for one hour and then incubated in the following primary antibodies overnight: EGFR 
(Millipore, 1:1000), pY1173 EGFR (Cell Signaling, 1:250), AKT (Cell Signaling, 1:250), pS473 
AKT (Cell Signaling, 1:250), or GAPDH (Sigma, 1:1000). Membranes were washed four times 
and secondary antibodies added for one hour, and electrogenerated chemiluminescence (ECL) 
was used to measure luminescence. 
 
Proliferation Assay 
Cells were plated in a 96 well plate at 3.3*103 cells per well. Four wells per treatment 
group were plated. After 24 hours, the media was replaced with treatment media supplemented 
with 10µM BrdU. The cells incubated for 24 hours and then were fixed with 4% 
paraformaldehyde for 15 minutes. The cells were washed twice with PBS and permeabilized 
with 0.3% Triton X in PBS for 15 minutes. The DNA was denatured using hydrochloric acid, 
and the cells were blocked using 10% goat serum and 0.3% Triton X for one hour. Primary 
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antibody (rat anti-BrdU, Abcam, 1:100) was incubated overnight. The cells were washed three 
times with PBS and incubated in secondary antibody (DyLight594-conjugated goat anti-rat, 
Jackson Immunoresearch, 1:200) for two hours. The cells were washed three times with PBS and 
counterstained with Hoechst 33528 (1:1000) for 10 minutes. Fluorescence images were acquired 
for three fields of view per well (n=12), and the number of cells per image was counted 
(ImageJ). 
 
Glucose and Lactate Assays 
Cells were plated at a density of 105 cells per 35 mm dish, and 24 hours later the media 
was replaced with treatment media. After 24 hours of treatment, glucose and lactate 
concentrations were measured according to the protocols of commercially available kits 
(Invitrogen; Eton Biosceience). 
 
Statistical Analyses 
Bar graphs are represented as mean ± standard error. Statistical significance was 
determined using two-way Wilcoxon rank sum tests in MATLAB (Mathworks). A p-value less 
than 0.05 indicated statistical significance. 
 
Results 
Redox ratio validation was performed by perturbing nonmalignant OKF6 cells with 4mM 
cyanide, which prevents oxidation of NADH to NAD+ in the electron transport chain [59]. This 
accumulation of NADH causes an increase in the optical redox ratio (Figure 8a) and verifies 
isolation of NADH and FAD fluorescence. The contribution from free NADH (α1) increases with 
 cyanide t
contribut
an increa
 
 
Figure 8
oral cell
an increa
NADH (
test; mea
 
T
SCC61, f
increased
reatment (F
ion from pro
sed FAD me
. Cyanide 
s (OKF6). (
se in the op
α1) and (c) 
n ± SEM. 
he optical 
rom the no
 redox ratio
igure 8b), c
tein-bound 
an lifetime 
treatment a
a) Cyanide 
tical redox
decreases th
metabolic e
nmalignant 
 compared 
ausing a dec
FAD (α1) d
(data not sh
lters redox
treatment (4
 ratio. (b) C
e contributi
ndpoints d
cell line, OK
with the OK
20 
reased NAD
ecreases wit
own).  
 ratio, NA
mM) disru
yanide trea
on of protei
ifferentiate 
F6 (Figure
F6 cells (p<
H mean lif
h cyanide tr
DH α1, and
pts the elect
tment incre
n-bound FA
the malign
 9). The ma
0.05). The 
etime (data 
eatment (Fi
 FAD α1 i
ron transpo
ases the con
D (α1). * p
ant cell lin
lignant cell
malignant c
not shown)
gure 8c), cau
n nonmalig
rt chain, cau
tribution of
<0.05, rank
es, SCC25
 lines showe
ell lines sh
. The 
sing 
nant 
sing 
 free 
 sum 
 and 
d an 
owed 
 
 increased
with the 
 
 
Figure 9
The norm
to nonm
phosphor
the malig
pathways
 
T
of EGFR
cetuxima
phosphor
 NADH α1 
OKF6 cells 
. Optical m
alized redo
alignant ce
ylation. (b-c
nant cell lin
. * p<0.05, 
he targeted 
 was asses
b treatmen
ylated Akt 
compared w
(p<0.05).  
etabolic en
x ratio incre
lls (OKF6)
) The contr
es compare
rank sum tes
treatments w
sed by mea
t. BGT226
(pAkt) bec
ith the OK
dpoints dis
ases for the
, indicating
ibution of fr
d with the n
t; mean ± S
ere validat
suring phos
 targeting 
ause PI3K 
21 
F6 cells (p<
 
tinguish m
 malignant c
 increased
ee NADH a
onmalignan
EM. 
ed by weste
phorylated 
of PI3K/
and mTOR
0.05) and 
alignant fr
ell lines (SC
 glycolysis
nd protein-
t cell line, 
rn blot (Figu
EGFR (pEG
mTOR wa
 activation 
increased FA
om nonma
C25 and S
 compared
bound FAD
reflecting sh
re 10). Cet
FR), whic
s assessed
drive Akt 
D α1 comp
lignant cell
CC61) comp
 with oxid
 (α1) increas
ifts in meta
uximab targ
h is absent 
 by meas
activation in
ared 
s. (a) 
ared 
ative 
e for 
bolic 
eting 
with 
uring 
 the 
 
 PI3K/Ak
cetuxima
performe
increased
EGFR an
 
 
Figure 1
blot for 
growth f
pathways
with BGT
 
R
qualitativ
fluoresce
redox rat
and decr
NADH a
t signaling p
b and BGT
d to charac
 pAkt, refl
d pEGFR co
0. Western
(a) SCC25 
actor alpha 
. Treatment
226 decrea
epresentativ
e visualizat
nce from th
ios of SCC2
ease with B
nd FAD refl
athway. pA
226 target 
terize the S
ecting upre
mpared wit
 blot verifi
and (b) SC
(TGF α) ac
 with cetux
ses phospho
e images o
ion of the re
e cytoplasm
5 and SCC
GT226 and 
ect cellular 
kt is absent
EGFR and 
CC25 and S
gulated PI3
h SCC25 ce
es molecula
C61 cells. 
tivate the e
imab decrea
rylated AKT
f SCC25 an
dox ratio, N
 was quan
61 cells sho
cisplatin tre
microenviro
22 
 with BGT2
PI3K/mTO
CC61 cell 
K. Addition
lls. 
r targeting
Epidermal 
pidermal gr
ses phospho
 (pAKT). 
d SCC61 c
ADH α1, an
tified acros
w no signif
atment (Fig
nment and p
26 treatmen
R, respectiv
lines (not sh
ally, SCC6
 of cetuxim
growth fact
owth factor
rylated EG
ells after 24
d FAD α1 (
s treatment
icant change
ure 12a). T
rotein-bind
t. These res
ely. Wester
own). SCC
1 cells exh
ab and B
or (EGF) a
 receptor (E
FR (pEGFR
 hours of tr
Figure 11). 
 groups and
s with cetu
he fluoresc
ing. NADH
ults indicate
n blot was
61 cells sh
ibited incre
GT226. We
nd transfor
GFR) and 
), and treat
eatment pro
NADH and 
 cell lines.
ximab treatm
ence lifetim
 α1 represen
 that 
 also 
owed 
ased 
 
stern 
ming 
AKT 
ment 
vide 
FAD 
 The 
ent, 
es of 
ts the 
23 
 
contribution from free NADH. For SCC25 cells, NADH α1 decreases with BGT226 and cisplatin 
treatment. For SCC61 cells, NADH α1 decreases with cetuximab, BGT226, and cisplatin 
treatment (Figure 12b). FAD α1 represents the contribution from protein-bound FAD. For SCC25 
and SCC61 cells, FAD α1 decreases with cisplatin treatment (Figure 12c). 
Proliferation was quantified as a standard measure of treatment response. Cetuximab 
treatment does not cause a statistically significant effect on proliferation, whereas BGT226 and 
cisplatin treatment decrease proliferation (Figure 12d).  Additionally, glycolytic rates were 
quantified after treatment. SCC25 shows decreased lactate production/glucose consumption with 
BGT226 and cisplatin treatment, and SCC61 shows decreased lactate production/glucose 
consumption with cetuximab, BGT226, and cisplatin treatment (Figure 12e). 
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with BrdU. The ratio of proliferating cells was calculated by dividing the number of BrdU-
labeled cells by the total number of cells per image. Treatment with cetuximab does not affect 
proliferation. Treatment with BGT226 or cisplatin treatment decrease proliferation. (e) The ratio 
of lactate production/glucose consumption reflects rates of glycolysis, which decreases after 
treatment with BGT226 and cisplatin in SCC25 cells and after treatment with cetuximab, 
BGT226, and cisplatin in SCC61 cells. * p<0.05 rank sum test, compared with control; mean ± 
SEM. 
 
 
For SCC25 (Table 1a), the free and protein-bound lifetimes of NADH and FAD (τ1 and 
τ2, respectively) show no significant change with any treatment (Table 1a). The NADH mean 
lifetime (τm) shows no change for any treatment, and the FAD mean lifetime increases with 
cisplatin treatment (p<0.05). For SCC61 (Table 1b), free and protein-bound NADH lifetimes 
show no significant change with cetuximab and BGT226 treatment and increase with cisplatin 
treatment (p<0.05). For SCC61, the protein-bound FAD lifetime (τ1) shows no change with any 
treatment, and the free FAD lifetime (τ2) increases with cisplatin treatment (p<0.05). The NADH 
mean lifetime (τm) increases with BGT226 and cisplatin treatment (p<0.05), and the FAD mean 
lifetime increases with cisplatin treatment (p<0.05). NADH and FAD α1 are also listed in Table 
1. 
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treatment efficacy could accelerate drug screening and identify optimal treatment regimens for 
individual patients, thereby improving patient outcomes.  
Isolation of NADH and FAD fluorescence emission was verified using cyanide 
perturbation (Figure 8). These shifts in the redox ratio and NADH and FAD lifetimes match 
published results [46][58][60][61]. Optical metabolic imaging distinguishes the malignant 
SCC25 and SCC61 cell lines from the nonmalignant OKF6 cell line (Figure 9). The increased 
redox ratio in HNSCC cells reflects increased reliance on glycolysis compared with oxidative 
phosphorylation, as expected in cancer cells (Warburg effect), and oncogene addiction, 
particularly to EGFR or PI3K, would be expected to increase the redox ratio [44]. This result 
agrees with previous findings that the redox ratio reports changes with malignancy [62]. The 
altered NADH and FAD fluorescence lifetimes reflect distinct signaling pathways in the HNSCC 
cells compared with nonmalignant cells. HNSCC cells exhibit modified intrinsic metabolic 
signaling that changes NADH binding sites [63], and the fluorescence lifetimes have been shown 
to change when NADH or FAD are bound to different enzymes [37]. Previous studies have also 
shown that fluorescence lifetime imaging distinguishes normal from precancer in the DMBA-
treated hamster cheek pouch model [49][50].  
 Changes in the redox ratio across treatment groups are consistent with proliferation rates 
after treatment. The redox ratio is a global measure of cellular metabolism, which drives 
proliferation. The redox ratio and proliferation ratio are unaffected by cetuximab treatment and 
show statistical differences with BGT226 and cisplatin treatment (Figure 12). The lack of effect 
from cetuximab treatment could be attributed to in vitro application as a single agent. In vivo, 
cetuximab initiates antibody-dependent cell-mediated cytotoxicity (ADCC) by binding to EGFR 
and recruiting natural killer cells and macrophages to digest the targeted cell. However, immune 
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cells are not present in these cell culture studies. Additionally, cetuximab is maximally effective 
in combination with radiotherapy and chemotherapy because it inhibits DNA repair mechanisms 
[17]. Conversely, BGT226 and cisplatin actively cause cell death in cell culture. BGT226 causes 
cell death by autophagy [43]. Cisplatin initiates apoptosis by crosslinking DNA, which interferes 
with mitosis and causes failure of DNA repair [64]. No previous literature has reported the 
effects of cetuximab or BGT226 on the optical redox ratio. Cisplatin has been shown to increase 
NADH and FAD fluorescence intensity and decrease FAD/(NADH+FAD) after 9 hours of 
treatment with 33µM cisplatin in primary human foreskin keratinocytes [65]. These results 
indicate a greater increase in NADH than FAD, which contradicts our measured decrease in 
NADH/FAD 24h after 176µM cisplatin treatment in SCC25 and SCC61 cells (Figure 12). 
However, the time-course of response, cell type-specific processes for cell death, and different 
concentrations of cisplatin could explain the differences in redox ratio. 
 The contribution from free NADH (NADH α1) shows shifts in protein-binding of NADH 
with BGT226 and cisplatin treatment in SCC25 and SCC61 cells as well as with cetuximab 
treatment in SCC61 cells (Figure 12b). The ratio of lactate production divided by glucose 
consumption reflects amounts of terminal glycolysis compared with total glucose metabolism. In 
glycolysis, glucose is consumed and pyruvate is produced. Pyruvate is either fermented into 
lactate as a terminal stage of glycolysis or converted to acetyl-coA as fuel for the citric acid 
cycle. Cetuximab treatment does not affect glycolysis rates in SCC25, but decreases glycolysis in 
SCC61. The decrease in glycolysis and NADH α1 in SCC61 cells indicates shifts in metabolic 
pathways in response to treatment. However, proliferation is not affected by cetuximab in 
SCC61, indicating compensation by effectors downstream of EGFR. Cetuximab has been shown 
to not affect short-term cell growth in SCC25, which could explain the lack of statistical 
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significance in the NADH α1 and glycolytic index [66]. BGT226 and cisplatin treatments 
decrease glycolysis in SCC25 and SCC61. The effect of cetuximab or BGT226 on SCC61 cells 
has not been cited in previous literature, and the effect of BGT226 on glycolysis has not been 
reported in any model. The measurement of glycolysis rates calculated by lactate 
production/glucose consumption is correlated with NADH α1 (0.81 Pearson’s correlation 
coefficient, p<0.05). No other measurements produced a statistically significant correlation 
coefficient with lactate production/glucose consumption or proliferation. Cisplatin treatment 
produces outliers that impacted the correlations, particularly between lactate production/glucose 
consumption and the redox ratio. Previous studies have shown a correlation between glucose 
uptake/lactate production and the optical redox ratio in breast cancer cells [46]. However, this 
correlation was determined for basal metabolic rates in cells without treatment, and cells from a 
different organ site could rely on different metabolic mechanisms. Additionally, the control 
SCC61 cells show a higher proliferation ratio than SCC25 (p<0.05) (Figure 12d), but no 
statistical difference in redox ratio (Figure 9a). This is in contrast to the similar lactate 
production/glucose consumption between the control SCC25 and SCC61. Although the trends in 
NADH α1 and redox ratio agree with the gold standards, they are not surrogate measurements of 
proliferation or the amount of glycolysis compared with total glucose metabolism. For example, 
alternative metabolic pathways such as beta oxidation of fatty acids, the pentose phosphate 
pathway, and glutaminolysis are all captured differently by these gold standard measurements 
and our optical measurements [67][68]. The contribution from protein-bound FAD (FAD α1) is 
unaffected by cetuximab and BGT226 treatments and decreases with cisplatin treatment (Figure 
12c).  
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 Early measures of treatment response could enable effective intervention while reducing 
the acute toxicities and serious morbidities from ineffective therapies. Molecular-level 
measurements that reflect cellular metabolism are well-suited to measure effects from cancer 
treatments that target metabolic pathways. The optical redox ratio and fluorescence lifetimes of 
NADH and FAD resolve a response after 24 hours of treatment with targeted therapies and 
chemotherapies in HNSCC cells. These results indicate that optical metabolic imaging shows 
promise to identify effective drug candidates during drug development. Additionally, applying 
optical metabolic imaging to measure treatment response early has potential to impact quality of 
life for HNSCC patients. 
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CHAPTER 3 
 
CONCLUSION AND FUTURE DIRECTIONS 
 
The current standard to measure cancer treatment response includes whole-body imaging, 
like PET, CT, x-ray, and MRI. However, these methods could be complemented with a 
molecular-level tool that utilizes endogenous contrast to measure treatment efficacy soon after 
therapy in HNSCC patients. This study exploits the autofluorescence intensities and lifetimes 
from the metabolic cofactors NADH and FAD to quantify treatment response in two HNSCC 
cell lines. Response was measured after 24 hours of treatment. Gold standard protocols for 
assessing treatment response, including western blot analysis, proliferation rate quantification, 
and glycolytic rate quantification, also measured response after treatment. These results indicate 
that optical metabolic endpoints have potential to measure early response to therapy in HNSCC.  
Future work will include the characterization of optical metabolic imaging in a more 
complex in vitro model, the application of optical metabolic imaging in vivo, and the design of a 
clinical system to measure these optical endpoints in HNSCC patients. Xenografts of human 
HNSCC cell lines will be grown in nude mice. In an initial study, tumors will be excised, 
digested, and grown in culture as organoids. These organoids will contain the cancer cells as well 
as the immune cells, fibroblasts, and other cell types growing in the tumor. This interaction of 
cell types will better mimic the complex in vivo tumor environment. The organoids will be 
treated with anti-cancer drugs and optical metabolic endpoints will be characterized. Gold 
standard response will include tumor growth curves in a separate cohort of mice.  
In a separate study, mice with HNSCC xenografts will be administered anti-cancer 
treatments, and two-photon fluorescence microscopy and fluorescence lifetime imaging will be 
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conducted in vivo. This study will harness the deep penetration and intrinsic depth sectioning of 
two-photon fluorescence excitation to quantify optical metabolic endpoints on a cellular-level 
resolution. This study will establish feasibility of these measurements in vivo. Gold standard 
measurements of proliferation and cell death will be quantified using histology as well as tumor 
growth curves in a separate cohort of mice.  
In vivo microscopy results will serve as measurements from an ideal system with high 
spatial, axial, and temporal resolution. Analysis will be conducted to determine the minimum 
requirements for a clinical system to be used in HNSCC patients. Data will be analyzed on a per-
cell basis compared with a per-image basis to determine minimum resolution requirements. 
Additionally, analysis using automated criteria for thresholding as well as no thresholding will be 
compared to determine thresholding requirements. Fluorescence lifetime decay curves will be 
undersampled to determine the minimum time resolution necessary for lifetime quantification.  
Optical metabolic imaging has potential to measure treatment response in HNSCC 
patients soon after therapy. Additionally, optical metabolic imaging could be implemented in 
preclinical models to screen for effective drugs and accelerate drug development. Furthermore, 
optical metabolic imaging could serve as a platform to predict optimal treatment regimens before 
administering therapy to patients. Improved treatment regiments and early assessment of 
treatment response in HNSCC patients has potential to reduce the morbidities and toxicities 
associated with ineffective therapy and to improve patient outcomes. 
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